Melhores Testes de função tiroideia (incluindo T3, T4, TSH) médicos em Turquia - TOP-52 médicos

O médico formou-se na Faculdade de Medicina da Universidade de Hacettepe e completou a residência no Hospital de Treinamento e Pesquisa Sisli Etfal de Istambul, seguido de uma bolsa de estudos no Instituto de Câncer da Universidade de Hacettepe.<\/p>

Especializando-se em oncologia, o médico tem vasta experiência no tratamento de vários tipos de câncer, incluindo câncer de mama, testicular, ovariano, pulmonar, de cabeça e pescoço, e gastrointestinal.<\/p>

O médico trabalhou em instituições de prestígio como o Centro de Câncer MD Anderson da Universidade do Texas, o Hospital de Treinamento da Universidade de Hitit em Corum e o Hospital Medical Park.<\/p>

Dr. Kemal Rasa is a general surgeon at Anadolu Medical Center in Istanbul. He is an editorial board member of the British Journal of Surgery. Dr. Rasa focuses on breast, pancreatic, and thyroid cancer surgeries. He also manages surgical infections and glucose metabolism disorders. His clinic partners with Johns Hopkins Medicine for American treatment standards.

• Former President of the Surgical Infection Society – Europe.
• Secretary of the World Surgical Infection Society board of directors.
• Authored over 65 national and international medical publications.
• Performs thyroidectomy, pancreatic enucleation, and breast cancer surgery.

Dr. Kezban Berberoglu is a professor of nuclear medicine at Anadolu Medical Center in Istanbul. She completed training at the Johns Hopkins University School of Medicine in Baltimore. Dr. Berberoglu specializes in nuclear oncology and nuclear cardiology. She treats thyroid and prostate cancers using radioisotope therapies. She is a member of the European Association of Nuclear Medicine.

• Performs Lutetium-177 and Actinium-225 therapies for oncology patients.
• Expert in PET-CT imaging using Gallium 68 for oncology cases.
• Member of the Turkish Nuclear Medicine Association cardiology work group.
• Works at an MTQUA Top 10 world hospital affiliated with Johns Hopkins.

O médico completou a educação médica na Universidade de Istambul, Faculdade de Medicina Cerrahpaşa, e conduziu estudos clínicos no Baylor College of Medicine e na The University of Texas Medical School. Ele passou nos exames USMLE e obteve o Certificado ECFMG para praticar nos EUA. Após retornar à Turquia, especializou-se em cirurgia geral na Universidade de Istambul e obteve um diploma em Cirurgia Laparoscópica da Universidade de Estrasburgo. Ele passou no exame do Conselho Europeu de Cirurgia Endócrina e é um dos cinco cirurgiões na Turquia com essa certificação. O médico tem mais de 10 anos de experiência em cirurgias laparoscópicas e minimamente invasivas, realizando mais de 2000 operações bem-sucedidas.<\/p>

O Dr. Sertkaya formou-se na Konya Meram Science High School em 2001 e entrou na Faculdade de Medicina da Universidade Gazi no mesmo ano, graduando-se em 2008. Concluiu a sua especialização em urologia no Hospital de Treinamento e Pesquisa Haydarpaşa Numune em 2014, tornando-se especialista em urologia.

Desde que se tornou especialista, ele tem focado na subespecialidade de Andrologia, participando de diversas sessões de formação e conferências, além de realizar cirurgias com alguns dos principais professores de Andrologia do mundo. Em 2017, ele passou nos exames de competência escritos e orais conduzidos pela Associação Europeia de Urologia, obtendo o título de “FEBU”.

Em 2020, o Dr. Sertkaya alcançou o título de Professor Associado de Urologia. A sua jornada em Urologia e Andrologia, que começou em 2008, continua no Andro Expertise Male Health and Aesthetics Center, que fundou em 2022. Ele atende pacientes na sua própria clínica e realiza cirurgias em hospitais afiliados.

Education and Specialization

• Faculty of Medicine, Hacettepe University
• 1999 - Akdeniz University, Faculty of Internal Medicine, Internal Medicine Specialization Training
• Internal Medicine Specialization Training in the USA, Akdeniz University (2013 - 2014)
• Internal Medicine Specialization Training in the USA (2013 - 2014) - Medical Oncology Department
• Akdeniz University, Faculty of Medicine, Department of Medical Oncology (Received Associate Professorship title)

Work Experience

• 2009 - Kayseri Training and Research Hospital, Hospital
• Acıbadem Kayseri
• 2017 - 2018 - Lara Private Anadolu Hospital
• 2018 - Medical Park Antalya Hospital Complex

Expertise

• Diagnosis of organ tumors
• Chemotherapy in cancer treatment
• Targeted cancer therapies
• Immunotherapy in cancer treatment
• Next-generation genetic research in cancer treatment
• Complementary medicine in cancer treatment
• Medical oncology

O médico formou-se na Escola de Medicina Cerrahpaşa da Universidade de Istambul em 1999 e completou uma residência em Medicina Interna lá em 2005. Especializando-se ainda mais em Endocrinologia e Doenças Metabólicas, o médico completou uma bolsa na Universidade Selçuk em 2010 e alcançou a Cátedra Associada em 2016.<\/p>

Reconhecido pela excelência em pesquisa científica, o médico recebeu prêmios no Congresso Nacional de Diabetes e na Universidade Selçuk em 2014. Com 42 artigos científicos internacionais e 16 locais, o trabalho foi citado 230 vezes. O médico contribuiu para 80 apresentações e participou de numerosos projetos científicos, incluindo aqueles financiados pela TUBİTAK.<\/p>

Os interesses clínicos incluem diabetes, doenças da tireoide e distúrbios hormonais.<\/p>

O médico se formou na Escola de Medicina Çapa da Universidade de Istambul em 1998 e completou uma residência em Radiodiagnóstico e Radiologia Intervencionista na Escola de Medicina Cerrahpaşa em 2002. Especializando-se em Radiologia Diagnóstica e Telerradiologia, bem como Radiologia Intervencionista, o médico participou de 12 congressos locais e um internacional, contribuindo com inúmeras apresentações orais e escritas. O médico ocupou cargos no Hospital Intercontinental Hisar, no Hospital Aéreo de Merzifon, no Centro Emar de Istambul e no Hospital de Treinamento e Pesquisa Haseki.<\/p>

O médico completou a educação médica na Escola de Medicina da Universidade de Trakya, na Escola de Medicina de Cerrahpaşa e na Escola de Medicina da Universidade de Kocaeli. Especializando-se em endocrinologia, o médico foca em diabetes, obesidade, distúrbios da tireoide e doenças da glândula pituitária e das glândulas suprarrenais.<\/p>

Com uma sólida formação acadêmica, o médico contribuiu para o campo médico com mais de 25 publicações nacionais e internacionais, demonstrando expertise e compromisso com o avanço do conhecimento médico nessas áreas.<\/p>

Prof. Dr. Sezer Sağlam is a medical oncologist at Gayrettepe Florence Nightingale Hospital. He specializes in gastrointestinal and breast cancers. He has contributed to cancer care through research, especially with his study on the best timing for surgery after neoadjuvant therapy in rectal cancer. This work has influenced global treatment protocols.

Dr. Sağlam has led clinical trials in targeted therapies and precision medicine. His research on liver-transplanted patients with hepatocellular carcinoma was nominated for the 2024 International Best Researcher Award. He is a member of ASCO, ESMO, and ENET. Dr. Sağlam provides personalized and evidence-based oncology care.

Dr. Saban Sec is a medical oncologist with experience at leading hospitals, including Haseki Training and Research Hospital, Prof. Dr. Cemil Taşcıoğlu City Hospital, and Bahçelievler Medikalpark Hospital. He currently represents specialist physicians in the Turkish Medical Oncology Association. He is also a member of the Istanbul Medical Chamber and the Turkish Medical Oncology Association.

Dr. Sec treats breast, lung, gastrointestinal, prostate, urogenital, head and neck cancers, as well as sarcomas and rare tumors. He has published many peer-reviewed articles on cancer prognosis, treatment outcomes, and survival rates. His research includes studies with large patient groups, such as 138 patients with HER2-positive metastatic gastric cancer. Dr. Sec focuses on prognostic factors and treatment responses in different cancers. He is dedicated to improving cancer care.

Education and Expertise

(1994 – 2000) - GATA Faculty of Medicine Ankara

(2003 – 2007) - GATA Medical Faculty Pediatrics and Diseases

(2008 -2011) - Ankara University Pediatric Endocrinology

(03.03.2014) - Associate Professorship, Pediatric Endocrinology

(17.07.2019) - Professorship, Istinye University Faculty of Medicine

Experience

(2001 – 2003) - Special Forces Command/Ankara

(2007 – 2008) - Etimesgut Military Hospital/Ankara

(2011 – 2013) - GATA Medical Faculty Hospital/Ankara

(2013-2015) - GATA Haydarpasa Training Hospital/Istanbul

(05.2015-09.10.2017) - May 2015-09.10.2017 - Süleymaniye Gynecology and Pediatrics Training and Research Hospital/Istanbul

(07.2015 – 01.2016) - Suleymaniye Gynecology and Pediatrics Training and Research Hospital Pediatrics Administrative Responsibility/Istanbul

01.2016 - 09.11.2017 - Suleymaniye Gynecology and Pediatrics Training and Research Hospital Pediatric Clinic Education Responsibility / Istanbul

(03.03.2016 - 30.10.2017) - Süleymaniye Gynecology and Pediatrics Training and Research Hospital Management

(2017-2020) - Istinye University Faculty of Medicine Faculty Member

(2020-Present) - Istanbul Aydın University Faculty of Medicine Faculty Member

(20.10.2020-Present) - Head of Department of Child Health and Diseases, Faculty of Medicine, Istanbul Aydın University

Courses and Certificates

2001 - Flight Doctor Course

2010 - Project Management Training Course

2013 - Basic Epidemiology course

2018 - Trainer Training Course

Professional Memberships

Pediatric Endocrinology and Diabetes Association

European Society of Pediatric Endocrinology (ESPE)

Istanbul Medical Chamber

Awards

İhsan Turan, Ian Hutchins, Bülent Hacıhamdioğlu, Leman Damla Kotan, Fatih Gürbüz, Mehmet Taştan, Ayça Ulubay, Eda Mengen, Bilgin Yüksel, Susan Wray, Ali Kemal Topaloğlu. CCDC141 Mutation in idiopathic hypogonadotropic hypogonadism. XVI. First Prize in Oral Presentation at the National Pediatric Endocrine and Diabetes Congress.

Bülent Hacıhamdioğlu, Gönül Öçal, Merih Berberoğlu, ZeynepŞıklar, Ercan Tutar, Suat Fitöz, Gökhan Nergizoğlu, Şenay Savaş Erdeve, Emine Çamtosun. Control of premature microvascular aging and cardiovascular performance in obese adolescents. XVI. was held in Samsun on 6-10 November 2012. Second Prize in Oral Presentation at the National Pediatric Endocrine and Diabetes Congress.

Z. Siklar, G. Ocal, M. Berberoglu, B. Hacıhamdioğlu, Ş. Savas Erdeve, Y. Egin, N. Akar. Control of hypercoagulability caused by obesity in children with endothelial microparticle level and thrombin generation test, and the relationship between risk and metabolic parameters. First Prize in Oral Presentation at the 55th Turkish National Pediatrics Congress held in Antalya on 12-16 October 2011

Z. Şıklar, V. Topçu, P. Kocaay, M. Berberoğlu, B. Hacıhamdioğlu, S.S. Erdeve, H.R. Ilgin, A. Tükün, G. Öcal. Clinical Characteristics of Our Cases with Mutation in the Androgen Receptor Gene. XVI. was held in Samsun on 6-10 November 2012. First Prize in Oral Presentation at the National Pediatric Endocrine and Diabetes Congress.

Associate Professor Dr. Yusuf AÇIKGÖZ
Specialization: Medical Oncology

Education:

• 2004-2011: İnönü University Faculty of Medicine
• 2011-2016: Ankara Numune Training and Research Hospital, Internal Medicine
• 2017-2022: Health Sciences University, Medical Oncology

Professional Experience:

• 2016-2017: Bingöl City Hospital, Internal Medicine
• 2021-2022: Health Sciences University, Medical Oncology
• 2022-2023: Kastamonu Education and Research Hospital, Medical Oncology
• 2023-2024: Ohio State University, Medical Oncology
• 2024-Present: Lokman Hekim University, Medical Oncology, Ankara Hospital

Clinical Trials, Courses, Certifications:

Clinical Trials:

• 2017-2021: Phase III, CheckMate-649 Study (Assistant Investigator)
• 2022-Present: Phase III, Fortitude-101 Study (Assistant Investigator)

Courses:

• 2018: Medicres Basic and Advanced Biostatistics Training Program (ongoing), Istanbul-Vienna
• 2019: Immuno-Oncology Education Course, March 1-2, 2019, Vienna, Central European Cooperative Oncology Group (CECOG)
• 2018: Good Clinical Practice Certification, April 7-8, 2018, Ankara, Health Sciences University
• 2017: Basic Oncology Training Program, November 25-26, 2017, Adana, Clinical Oncology Society
• 2016: Basic Ultrasonography Course (10 hours theoretical + 10 hours practical), September 24-25, 2016, Ankara, Turkish Emergency Medicine Association

Certifications:

• Ongoing: ECFMG Certification
• 2024: CITI Responsible Conduct of Research (The Ohio State University)
• 2024: CITI IACUC-Laboratory Animal Research (The Ohio State University)
• 2024: CITI Human Subjects Protection (The Ohio State University)
• 2024: CITI Good Clinical Practice (The Ohio State University)
• 2023: Occupational English Test (OET)
• 2019: International English Language Testing System (IELTS), Total Score: 6.5, May 26, 2019, Ankara, British Council
• 2017: USMLE Step 2 CK Exam; Score: 244, February 7, 2017
• 2016: USMLE Step 1 Exam; Score: 215, August 25, 2016

Memberships:

• American Society of Clinical Oncology (ASCO) - 2022
• Turkish Society of Medical Oncology - 2020

Education:

• Degree: Faculty of Medicine, Trakya University, 2009
• Medical Specialty: Internal Medicine, Bakırköy Dr. Sadi Konuk Training and Research Hospital, 2010-2014
• Specialist Doctor: Internal Medicine, Kanuni Sultan Süleyman Training and Research Hospital, 2014-2019
• Specialist Doctor: Internal Medicine, Turkish Hospital Internal Medicine Clinic, Qatar, 2019-2020
• Specialist Doctor: Internal Medicine, Istanbul Medipol University Hospital Mega Hospital Internal Medicine Department, 2020-2024
• Associate Professor Doctor: Internal Medicine, Istanbul Medipol University Medipol Acıbadem Regional Hospital, 2024-Present.

Roles in Projects:

Sub investigator (Assistant Researcher) in the SOUL Study: Cardiovascular Outcome Research of Semaglutide in Type 2 Diabetic Patients, approved by the Turkish Medicines and Medical Devices Agency on May 22, 2019.

Sub investigator (Assistant Researcher) in the international study “SCALE™ Insulin”: Efficacy and Safety of Liraglutide 3.0 mg in Overweight or Obese Patients with Type 2 Diabetes Treated with Basal Insulin (Study Code: NN8022-4272), conducted by Novo Nordisk A.Ş.

Subinvestigator (Assistant Researcher) in the international study NN5401-4266 StepByStep Intensification conducted by Novo Nordisk.

Assistant Researcher in the study "A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes (SUSTAIN 11)" (2019-2020).

Assistant Researcher in the PIONEER 1 study: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes.

Education and Expertise

• 1989 BORNOVA ANATOLIAN HIGH SCHOOL
• UNDERGRADUATE DEGREE 1995 EGE UNIVERSITY/ FACULTY OF MEDICINE
• SPECIALIZATION IN MEDICINE 2001 DOKUZ EYLÜL UNIVERSITY/MEDICAL FACULTY INTERNAL MEDICINE DEPARTMENT
• MEDICAL SPECIALIST 2005 DOKUZ EYLÜL UNIVERSITY FACULTY OF MEDICINE ENDOCRINE AND METABOLISM DISEASES

Biography

Our doctor admits patients aged or older than 15.

Medical Education

School of Medicine, Ege University

Medical Residency

Department of Internal Medicine, School of Medicine, Dokuz Eylül University

Department of Endocrinology, School of Medicine, Dokuz Eylül University

Areas of Interest

Diabetes Mellitus

Thyroid Diseases

Pituitary Diseases

Hirsutism

Osteoporosis

Membership

Turkish Society of Endocrinology and Metabolism

Experience

• 2005-2009 Private Western Anatolia Central Hospital
• 2009-2011 Private Healing Hospital
• 2011-2016 Private Izmir Sifa University
• 2016-2023 Izmir Medical Point Hospital

Professional Memberships

• Turkish Medical Association
• Turkish Endocrinology and Metabolism Association

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

Dr. Hakan Duger is a specialist in Endocrinology and Metabolic Diseases. He has worked at Gaziantep Özel Defa Life Hospital since 2023. He previously served at Kilis Prof. Dr. Alaeddin Yavaşca State Hospital from 2021 to 2023.

Education and training: Gazi University Faculty of Medicine (2006–2012). Internal Medicine residency at Uludağ University (2012–2017). Endocrinology and Metabolic Diseases training at Ankara Numune Training and Research Hospital (2017–2018) and Ankara Dışkapı Yıldırım Beyazıt Training and Research Hospital (2018–2021). He also served as an Internal Medicine specialist at Şanlıurfa Mehmet Akif İnan Training and Research Hospital (2017–2019).

Professional memberships: Turkish Medical Association. Turkish Society of Endocrinology and Metabolism. Turkish Diabetes Association. Clinical Endocrinology and Diabetes Association.